{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:03:20Z","timestamp":1786705400910,"version":"build-2736575974"},"reference-count":147,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T00:00:00Z","timestamp":1401408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["opendentistryjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TODENTJ"],"published-print":{"date-parts":[[2014,5,30]]},"abstract":"<jats:p>The non-antimicrobial properties of tetracyclines such as anti-inflammatory, proanabolic and anti-catabolic actions make them effective pharmaceuticals for the adjunctive management of chronic inflammatory diseases. An over-exuberant inflammatory response to an antigenic trigger in periodontitis and other chronic inflammatory diseases could contribute to an autoimmune element in disease progression. Their adjunctive use in managing periodontitis could have beneficial effects in curbing excessive inflammatory loading from commonly associated comorbidities such as CHD, DM and arthritis. Actions of tetracyclines and their derivatives include interactions with MMPs, tissue inhibitors of MMPs, growth factors and cytokines. They affect the sequence of inflammation with implications on immunomodulation, cell proliferation and angiogenesis; these actions enhance their scope, in treating a range of disease entities. Non-antimicrobial chemically modified tetracyclines (CMTs) sustain their diverse actions in organ systems which include anti-inflammatory, anti-apoptotic, anti-proteolytic actions, inhibition of angiogenesis and tumor metastasis. A spectrum of biological actions in dermatitis, periodontitis, atherosclerosis, diabetes, arthritis, inflammatory bowel disease, malignancy and prevention of bone resorption is particularly relevant to minocycline. Experimental models of ischemia indicate their specific beneficial effects. Parallel molecules with similar functions, improved Zn binding and solubility have been developed for reducing excessive MMP activity. Curbing excessive MMP activity is particularly relevant to periodontitis, and comorbidities addressed here, where specificity is paramount. Unique actions of tetracyclines in a milieu of excessive inflammatory stimuli make them effective therapeutic adjuncts in the management of chronic inflammatory disorders. These beneficial actions of tetracyclines are relevant to the adjunctive management of periodontitis subjects presenting with commonly prevalent comorbidities addressed here.<\/jats:p>","DOI":"10.2174\/1874210601408010109","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T11:31:34Z","timestamp":1402918294000},"page":"109-124","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities"],"prefix":"10.2174","volume":"8","author":[{"given":"Aruni","family":"Tilakaratne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mena","family":"Soory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.phrs.2010.10.003","volume":"63","author":"Golub LM","year":"2011","unstructured":"Golub LM. Introduction and background. Pharmacol Res 2011; 63 : 99-101.","journal-title":"Pharmacol Res"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-0765.2004.00696.x","volume":"39","author":"Choi DH","year":"2004","unstructured":"Choi DH, Moon IS, Choi BK. Effects of sub-antimicrobial dose of doxycycline therapy on crevicular fluid MMP-8 and gingival tissue MMP-9. TIMP-1 and IL-6 levels in chronic periodontitis. J Periodontal Res 2004; 39 : 20-6.","journal-title":"J Periodontal Res"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.phrs.2010.10.006","volume":"63","author":"Payne JB","year":"2011","unstructured":"Payne JB, Golub LM. Using tetracyclines to treat osteoporotic\/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol Res 2011; 63 : 121-9.","journal-title":"Pharmacol Res"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"13644","DOI":"10.1021\/jp3079748","volume":"116","author":"Marcial BL","year":"2012","unstructured":"Marcial BL, Sousa SF, Barbosa IL, Dos Santos HF, Ramos MJ. Chemically modified tetracyclines as inhibitors of MMP-2 matrix metalloproteinase: a molecular and structural study. J Phys Chem B 2012; 116 : 13644-54.","journal-title":"J Phys Chem B"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/SHK.0b013e318245f2f9","volume":"37","author":"Roy SK","year":"2012","unstructured":"Roy SK, Kubiak BD, Albert SP. Chemically-modified tetracycline-3 prevents acute respiratory distress syndrome in a porcine model of sepsis plus ischemia\/reperfusion lung injury. Shock 2012; 37 : 424-32.","journal-title":"Shock"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","volume":"169","author":"Garrido-Mesa N","year":"2013","unstructured":"Garrido-Mesa N, Zarzuelo A, G\u00e1lvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013; 169 : 337-52.","journal-title":"Br J Pharmacol"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/sj.bdj.2013.682","volume":"215","author":"Johnston S","year":"2013","unstructured":"Johnston S. Feeling blue?.Minocycline-induced staining of the teth.oral mucosa., sclerae and ears a case report. Br Dent J 2013; 215 : 71-3.","journal-title":"Br Dent J"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.2174\/092986712802884295","volume":"19","author":"Zhang Y","year":"2012","unstructured":"Zhang Y, Gu Y, Lee HM. Design. synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem 2012; 19 : 4348-58.","journal-title":"Curr Med Chem"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"191670","DOI":"10.1155\/2011\/191670","volume":"2011","author":"Devy L","year":"2011","unstructured":"Devy L, Dransfield DT. New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem Res Int 2011; 2011 : 191670.","journal-title":"Biochem Res Int"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.phrs.2012.10.006","volume":"67","author":"Garrido-Mesa N","year":"2013","unstructured":"Garrido-Mesa N, Zarzuelo A, G\u00e1lvez J. What is behind the non-antibiotic properties of minocycline?. Pharmacol Res 2013; 67 : 18-30.","journal-title":"Pharmacol Res"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2010.10.004","volume":"63","author":"Griffin MO","year":"2011","unstructured":"Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res 2011; 63 : 102-7.","journal-title":"Pharmacol Res"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.det.2007.01.012","volume":"25","author":"Webster G","year":"2007","unstructured":"Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007; 25 : 133-5.","journal-title":"Dermatol Clin"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1471-4159.2005.03219.x","volume":"94","author":"Kraus RL","year":"2005","unstructured":"Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang a, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 2005; 94 : 819-27.","journal-title":"J Neurochem"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10787-011-0077-5","volume":"19","author":"Leite LM","year":"2011","unstructured":"Leite LM, Carvalho AGG, Tavares Ferreira PLF. Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study. Inflammopharmacology 2011; 19 : 99-110.","journal-title":"Inflammopharmacology"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/01.STR.0000206281.77178.ac","volume":"37","author":"Yenari MA","year":"2006","unstructured":"Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier con-stituents: improvement by minocycline in vivo and in vitro. Stroke 2006; 37 : 1087-93.","journal-title":"Stroke"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/BRS.0b013e3182895587","volume":"38","author":"Sonmez E","year":"2013","unstructured":"Sonmez E, Kabatas S, Ozen O. Minocycline treatment inhibits lipid peroxidation. preserves spinal cord ultrastructure and improves functional outcome after traumatic spinal cord injury in the rat. Spine 2013; 38 : 1253-9.","journal-title":"Spine"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1902\/jop.2003.74.1.103","volume":"74","author":"Takashiba S","year":"2003","unstructured":"Takashiba S, Naruishi K, Murayama Y. Perspective of cytokine regulation for periodontal treatment: fibroblast biology. J Periodontol 2003; 74 : 103-.","journal-title":"J Periodontol"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/18715303113139990040","volume":"7","author":"El-Shinnawi U","year":"2013","unstructured":"El-Shinnawi U, Soory M. Associations between periodontitis and systemic inflammatory diseases: response to treatment. Recent Pat Endocr Metab Immune Drug Discov 2013; 7 : 169-88.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.phrs.2010.12.003","volume":"63","author":"Caton J","year":"2011","unstructured":"Caton J, Ryan ME. Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol Res 2011; 63 : 114-20.","journal-title":"Pharmacol Res"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1902\/jop.2008.080231","volume":"79","author":"Serhan CN","year":"2008","unstructured":"Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol 2008; 79 : 1520-6.","journal-title":"J Periodontol"},{"key":"refR21","volume":"4","author":"Gu Y","year":"2012","unstructured":"Gu Y, Walker C, Ryan ME, Payne JB, Golub LM. Non-antibacterial tetracycline formulations clinical applications in dentistry and medicine.Epub 2012 Oct 12 J Oral Microbiol 2012; 4","journal-title":"J Oral Microbiol."},{"key":"refR22","first-page":"581207","volume":"2012","author":"Moreno Villagrana AP","year":"2012","unstructured":"Moreno Villagrana AP, Gomez Clavel JF. Antimicrobial or sub antimicrobial antibiotic therapy as an adjunct to the nonsurgical periodontal treatment: a meta-analysis. ISRN Dent 2012; 2012 : 581207- 11.","journal-title":"ISRN Dent"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.archoralbio.2006.10.005","volume":"52","author":"Gomes PS","year":"2007","unstructured":"Gomes PS, Fernandes MH. Effect of therapeutic levels of doxycycline and minocycline in the proliferation and differentiation of human bone marrow osteoblastic cells. Arch Oral Biol 2007; 52 : 251-9.","journal-title":"Arch Oral Biol"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1600-0757.2006.00166.x","volume":"43","author":"Kirkwood KL","year":"2007","unstructured":"Kirkwood KL, Cirelli JA, Rogers JE, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007; 43 : 294-315.","journal-title":"Periodontol 2000"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0091270010373929","volume":"51","author":"Basegmez C","year":"2011","unstructured":"Basegmez C, Berber L, Yalcin F. Clinical and biochemical efficacy of minocycline in non-surgical periodontal therapy: a randomized controlled pilot study. J Clin Pharmacol 2011; 51 : 915-22.","journal-title":"J Clin Pharmacol"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.4103\/0975-7406.100315","volume":"4","author":"Honibald EN","year":"2012","unstructured":"Honibald EN, Mathew S, Padmanaban J, Sundaram E, Ramamoorthy RD. Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory perio-dontal disease. J Pharm Bioallied Sci 2012; 4 (Suppl 2 ) : S417-21.","journal-title":"J Pharm Bioallied Sci"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1902\/jop.2008.080174","volume":"79","author":"Giannobile WV","year":"2008","unstructured":"Giannobile WV. Host-response therapeutics for periodontal diseases. J Periodontol 2008; 79 : 1592-600.","journal-title":"J Periodontol"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1749-6632.1999.tb07693.x","volume":"878","author":"Ashley RA","year":"1999","unstructured":"Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease.SDD Clinical Research Team. Ann NY Acad Sci 1999; 878 : 335-46.","journal-title":"Ann NY Acad Sci"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/07853890600800103","volume":"38","author":"Sorsa T","year":"2006","unstructured":"Sorsa T, Tj\u00e4derhane L, Konttinen YT. Matrix metalloproteinases: contribution to pathogenesis.diagnosis and treatment of periodontal inflammation. Ann Med 2006; 38 : 306-21.","journal-title":"Ann Med"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/08959374980120011501","volume":"12","author":"Ciancio S","year":"1998","unstructured":"Ciancio S, Ashley R. Safety and efficacy of subantimicrobial-dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res 1998; 12 : 27-31.","journal-title":"Adv Dent Res"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1902\/jop.2000.71.4.521","volume":"71","author":"Caton JG","year":"2000","unstructured":"Caton JG, Ciancio SG, Blieden TM. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000; 71 : 521-32.","journal-title":"J Periodontol"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/0253-7613.93841","volume":"44","author":"Agnihotri R","year":"2012","unstructured":"Agnihotri R, Gaur S. Chemically modified tetracyclines: novel therapeutic agents in the management of chronic periodontitis. Indian J Pharmacol 2012; 44 : 161-7.","journal-title":"Indian J Pharmacol"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1902\/annals.2003.8.1.12","volume":"8","author":"Reddy MS","year":"2003","unstructured":"Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase. anti-inflammaory.and bone-sparing agents a systematic review. Ann Periodontol 2003; 8 : 12-37.","journal-title":"Ann Periodontol"},{"key":"refR34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1902\/jop.2008.070375","volume":"79","author":"Preshaw PM","year":"2008","unstructured":"Preshaw PM, Novak MJ, Mellonig J. Modified release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol 2008; 79 : 440-52.","journal-title":"J Periodontol"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1902\/jop.2004.75.3.441","volume":"75","author":"Gapski R","year":"2004","unstructured":"Gapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV. Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial. J Periodontol 2004; 75 : 441-52.","journal-title":"J Periodontol"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/0022034510363367","volume":"89","author":"Golub LM","year":"2010","unstructured":"Golub LM, Lee HM, Stoner JA. Doxycycline effects on serum bone biomarkers in post-menopausal women. J Dent Res 2010; 89 : 644-9.","journal-title":"J Dent Res"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1600-051X.2007.01114.x","volume":"34","author":"Reinhardt RA","year":"2007","unstructured":"Reinhardt RA, Stoner JA, Golub LM. Efficacy of sub-antimicrobial dose doxycycline in post-menopausal women: clinical outcomes. J Clin Periodontol 2007; 34 : 768-5.","journal-title":"J Clin Periodontol"},{"key":"refR38","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1902\/jop.2008.070623","volume":"79","author":"Golub LM","year":"2008","unstructured":"Golub LM, Lee HM, Stoner JA. Subantimicrobial dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol 2008; 79 : 1409-8.","journal-title":"J Periodontol"},{"key":"refR39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.14219\/jada.archive.2011.0165","volume":"142","author":"Payne JB","year":"2011","unstructured":"Payne JB, Golub LM, Stoner JA. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation. J Am Dent Assoc 2011; 142 : 262-73.","journal-title":"J Am Dent Assoc"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2460\/ajvr.74.1.130","volume":"74","author":"Kim SE","year":"2013","unstructured":"Kim SE, Kim S, Jeong M. Experimental determination of a sub antimicrobial dosage of doxycycline hyclate for treatment of periodontitis in Beagles. Am J Vet Res 2013; 74 : 130-5.","journal-title":"Am J Vet Res"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1902\/jop.2011.110026","volume":"82","author":"Sgolastra F","year":"2011","unstructured":"Sgolastra F, Petrucci A, Gatto R, Giannoni M, Monaco A. Long-term efficacy of subantimicrobial-dose doxycycline as an adjunctive treatment to scaling and root planing: a sys-tematic review and meta-analysis. J Periodontol 2011; 82 : 1570-81.","journal-title":"J Periodontol"},{"key":"refR42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.phrs.2010.10.007","volume":"63","author":"Monk E","year":"2011","unstructured":"Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res 2011; 63 : 130-45.","journal-title":"Pharmacol Res"},{"key":"refR43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","volume":"54","author":"Sapadin AN","year":"2006","unstructured":"Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54 : 258-65.","journal-title":"J Am Acad Dermatol"},{"key":"refR44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1999.tb07692.x","volume":"878","author":"Ryan ME","year":"1999","unstructured":"Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMP mediated events in diabetes. Ann NY Acad Sci 1999; 878 : 311-4.","journal-title":"Ann NY Acad Sci"},{"key":"refR45","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.phrs.2010.12.011","volume":"63","author":"Garrido-Mesa N","year":"2011","unstructured":"Garrido-Mesa N, Camuesco D, Arribas B et?al. The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. Pharmacol Res 2011; 63 : 308-19.","journal-title":"Pharmacol Res"},{"key":"refR46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1734-1140(11)70504-7","volume":"63","author":"Cai Z","year":"2011","unstructured":"Cai Z, Zhao Y, Yao S, Bin Zhao B. Increases in \u00df-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-?B pathway activation. Pharmacol Rep 2011; 63 : 381-91.","journal-title":"Pharmacol Rep"},{"key":"refR47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jacc.2003.09.050","volume":"43","author":"Scarabelli TM","year":"2004","unstructured":"Scarabelli TM, Stephanou A, Pasini E et?al. Minocycline inhibits caspase activation and reactivation. increases the ratio of XIAP to smac\/DIBLO.and reduces the mitochon-drial leakage of cytochrome C and smac\/DIABLO. J Am Coll Cardiol 2004; 43 : 865-74.","journal-title":"J Am Coll Cardiol"},{"key":"refR48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.phrs.2011.05.002","volume":"64","author":"Bench TJ","year":"2011","unstructured":"Bench TJ, Jeremias A, Brown DL. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol Res 2011; 64 : 561-6.","journal-title":"Pharmacol Res"},{"key":"refR49","doi-asserted-by":"crossref","first-page":"9685","DOI":"10.1073\/pnas.0600554103","volume":"103","author":"Alano CC","year":"2006","unstructured":"Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006; 103 : 9685-0.","journal-title":"Proc Natl Acad Sci USA"},{"key":"refR50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1471-4159.2005.03520.x","volume":"96","author":"Nikodemova M","year":"2006","unstructured":"Nikodemova M, Duncan ID, Watters JJ. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and I?Ba degradation in a stimulus-specific manner in microglia. J Neurochem 2006; 96 : 314-23.","journal-title":"J Neurochem"},{"key":"refR51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1742-2094-5-15","volume":"5","author":"Henry CJ","year":"2008","unstructured":"Henry CJ, Huang Y, Wynne A et?al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation. sickness behaior.and anhedonia. J Neuroinflamm 2008; 5 : 15.","journal-title":"J Neuroinflamm"},{"key":"refR52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4196\/kjpp.2011.15.2.115","volume":"15","author":"Park CH","year":"2011","unstructured":"Park CH, Shin TK, Lee HY, Kim SJ, Lee WS. Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice. Korean J Physiol Pharmacol 2011; 15 : 115-22.","journal-title":"Korean J Physiol Pharmacol"},{"key":"refR53","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bbi.2011.01.015","volume":"25","author":"Markovic DS","year":"2011","unstructured":"Markovic DS, Vinnakota K, van Rooijen N et?al. Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun 2011; 25 : 624-8.","journal-title":"Brain Behav Immun"},{"key":"refR54","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4161\/auto.7.2.14043","volume":"7","author":"Liu WT","year":"2011","unstructured":"Liu WT, Lin CH, Hsiao M, Gean PW. Minocycline inhibits the growth of glioma by inducing autophagy. Autophagy 2011; 7 : 166-75.","journal-title":"Autophagy"},{"key":"refR55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.taap.2009.02.026","volume":"237","author":"Huang TY","year":"2009","unstructured":"Huang TY, Chu HC, Lin YL et?al. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol Appl Pharmacol 2009; 237 : 69-82.","journal-title":"Toxicol Appl Pharmacol"},{"key":"refR56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/01.MIB.0000225330.38119.c7","volume":"12","author":"Perencevich M","year":"2006","unstructured":"Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006; 12 : 651-4.","journal-title":"Inflamm Bowel Dis"},{"key":"refR57","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ibd.20377","volume":"14","author":"Schultz M","year":"2008","unstructured":"Schultz M. Clinical use of E.coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14 : 1012-8.","journal-title":"Inflamm Bowel Dis"},{"key":"refR58","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.bcp.2011.09.004","volume":"82","author":"Garrido-Mesa N","year":"2011","unstructured":"Garrido-Mesa N, Utrilla P, Comalada M et?al. The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochem Pharmacol 2011; 82 : 1891-900.","journal-title":"Biochem Pharmacol"},{"key":"refR59","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1474-4422(04)00937-8","volume":"3","author":"Yong VW","year":"2004","unstructured":"Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004; 3 : 744-51.","journal-title":"Lancet Neurol"},{"key":"refR60","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1073858405275175","volume":"11","author":"Stirling DP","year":"2005","unstructured":"Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 2005; 11 : 308-22.","journal-title":"Neuroscientist"},{"key":"refR61","doi-asserted-by":"crossref","first-page":"F91","DOI":"10.1152\/ajprenal.00051.2004","volume":"288","author":"Sutton TA","year":"2005","unstructured":"Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2005; 288 : F91-7.","journal-title":"Am J Physiol Renal Physiol"},{"key":"refR62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/156720107781023938","volume":"4","author":"Jordan J","year":"2007","unstructured":"Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF. Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 2007; 4 : 225-31.","journal-title":"Curr Drug Deliv"},{"key":"refR63","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/01.wnl.0000277487.04281.db","volume":"69","author":"Lampl Y","year":"2007","unstructured":"Lampl Y, Boaz M, Gilad R. Minocycline treatment in acute stroke: an open-label. evaluator-blinded study. Neurol 2007; 69 : 1404-0.","journal-title":"Neurol"},{"key":"refR64","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1161\/CIRCULATIONAHA.108.769331","volume":"117","author":"Andrassy M","year":"2008","unstructured":"Andrassy M, Volz HC, Igwe JC et?al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008; 117 : 3216-26.","journal-title":"Circulation"},{"key":"refR65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2010.03.059","volume":"638","author":"Hu X","year":"2010","unstructured":"Hu X, Zhou X, He Betal. Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 2010; 638 : 84-9.","journal-title":"Eur J Pharmacol."},{"key":"refR66","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FJC.0b013e3181faeaf0","volume":"56","author":"Tao R","year":"2010","unstructured":"Tao R, Kim SH, Honbo N, Karliner JS, Alano CC. Minocycline protects cardiac myocytes against simulated ischemia reperfusion injury by inhibiting poly (ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 2010; 56 : 659-8.","journal-title":"J Cardiovasc Pharmacol."},{"key":"refR67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.atherosclerosis.2011.05.041","volume":"219","author":"Shahzad K","year":"2011","unstructured":"Shahzad K, Thati M, Wang Hetal. Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1). Atherosclerosis 2011; 219 : 74-83.","journal-title":"Atherosclerosis."},{"key":"refR68","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.phrs.2011.06.023","volume":"64","author":"Gu Y","year":"2011","unstructured":"Gu Y, Lee HM, Sorsa T. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease a mechanistic link between local and systemic inflammation. Pharmacol Res 2011; 64 : 573-9.","journal-title":"Pharmacol Res."},{"key":"refR69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-3083.2012.02718.x","volume":"76","author":"Alfakry H","year":"2012","unstructured":"Alfakry H, Sinisalo J, Paju S. The association of serum neutrophil markers and acute coronary syndrome. Scand J Immunol 2012; 76 : 181-7.","journal-title":"Scand J Immunol."},{"key":"refR70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.phrs.2010.10.005","volume":"63","author":"Sorsa T","year":"2011","unstructured":"Sorsa T, Tervahartiala T, Leppilahti J. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res 2011; 63 : 108-3.","journal-title":"Pharmacol Res."},{"key":"refR71","doi-asserted-by":"crossref","unstructured":"Preshaw PM, Ed. Warnakulasuriya S and Tilakaratne WM. In Oral Medicine & Pathology a guide to diagnosis and management Chapter 3: Periodontal disease . 1st ed.. Publishers New Delhi.: Jaypee Brothers Medical 2014; pp. 50-81.","DOI":"10.5005\/jp\/books\/12147_3"},{"key":"refR72","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1743-7075-9-88","volume":"9","author":"Marchetti E","year":"2012","unstructured":"Marchetti E, Monaco A, Procaccini L. Periodontal disease: the influence of metabolic syndrome. Nutr Metab 2012; 9 : 88.","journal-title":"Nutr Metab"},{"key":"refR73","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1023\/A:1025622815579","volume":"18","author":"Merchant AT","year":"2003","unstructured":"Merchant AT, Pitiphat W, Rimm EB, Joshipura K. Increased physical activity decreases periodontitis risk in men. Eur J Epidemiol 2003; 18 : 891-.","journal-title":"Eur J Epidemiol"},{"key":"refR74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.09.011","volume":"40","author":"Alikhani M","year":"2007","unstructured":"Alikhani M, Alikhani Z, Boyd C. Advanced glycation end products stimulate osteoblast apoptosis via MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40 : 345-53.","journal-title":"Bone"},{"key":"refR75","first-page":"57","volume":"4","author":"Borges I Jr","year":"2007","unstructured":"Borges I Jr, Moreira EA, Filho DW, de Oliveira TB, da Silva MB, Frode TS. Pro-inflammatory and oxidative stress markers in patients with periodontal disease. Mediators Inflamm 2007; 4 : 57-94.","journal-title":"Mediators Inflamm"},{"key":"refR76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.0303-6979.2004.00432.x","volume":"31","author":"Montebugnoli L","year":"2004","unstructured":"Montebugnoli L, Servidio D, Miaton RA, Prati C, Tricoci P, Melloni C. Poor oral health is associated with coronary heart disease and elevated systemic inflammatory and haemostatic factors. J Clin Periodontol 2004; 31 : 25-9.","journal-title":"J Clin Periodontol"},{"key":"refR77","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1902\/jop.2005.76.8.1362","volume":"76","author":"Al-Zahrani MS","year":"2005","unstructured":"Al-Zahrani MS, Borawski EA, Bissada NF. Periodontitis and three health-enhancing behaviours: maintaining normal weight. engaging in recommended level of exercise and consuming a high quality diet. J Periodontol 2005; 76 : 1362-6.","journal-title":"J Periodontol"},{"key":"refR78","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/oby.2003.145","volume":"11","author":"Pischon T","year":"2003","unstructured":"Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rim EB. Leisure time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003; 11 : 1055-64.","journal-title":"Obes Res"},{"key":"refR79","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1210\/jc.2004-0305","volume":"89","author":"Hansel B","year":"2004","unstructured":"Hansel B, Giral P, Nobecourt E. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89 : 4963-71.","journal-title":"J Clin Endocrinol Metab"},{"key":"refR80","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1161\/01.ATV.0000190660.32863.cd","volume":"25","author":"Koyama H","year":"2005","unstructured":"Koyama H, Shoji T, Yokoyama M. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 : 2587-93.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"refR81","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cardiores.2004.05.001","volume":"63","author":"Basta G","year":"2004","unstructured":"Basta G, Schmidt AM, Decaterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63 : 582-92.","journal-title":"Cardiovasc Res"},{"key":"refR82","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2011.05.005","volume":"64","author":"Castro MM","year":"2011","unstructured":"Castro MM, Kandasamy AD, Youssef N, Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular disease. Pharmacol Res 2011; 64 : 551-60.","journal-title":"Pharmacol Res"},{"key":"refR83","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.ATV.0000121571.78696.dc","volume":"24","author":"Brown DL","year":"2004","unstructured":"Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004; 24 : 733-8.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"refR84","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"Ridker PM","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N Engl J Med 2008; 359 : 2195-07.","journal-title":"N Engl J Med"},{"key":"refR85","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00011-013-0626-z","volume":"62","author":"Salminen A","year":"2013","unstructured":"Salminen A, Pussinen PJ, Payne JB. Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages. Inflamm Res 2013; 62 : 711-20.","journal-title":"Inflamm Res"},{"key":"refR86","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1161\/01.STR.0000038098.04291.F6","volume":"33","author":"Axisa B","year":"2002","unstructured":"Axisa B, Loftus IM, Naylor AR. Prospective. randomzed.double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002; 33 : 2858-64.","journal-title":"Stroke"},{"key":"refR87","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0002-9440(10)64929-2","volume":"160","author":"Bendeck MP","year":"2002","unstructured":"Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth. migraion.and matrix remodelling after arterial le-sions. Am J Pathol 2002; 160 : 1089-95.","journal-title":"Am J Pathol"},{"key":"refR88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mva.2002.125018","volume":"36","author":"Baxter BT","year":"2002","unstructured":"Baxter BT, Pearce WH, Waltke EA. Prolonged administration of doxycycline in patients with small asymptomatic aortic aneurysms: report of a prospective (Phase II) multi-centre study. J Vasc Surg 2002; 36 : 1-12.","journal-title":"J Vasc Surg"},{"key":"refR89","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.287.18.2414","volume":"287","author":"Ludvig DS","year":"2002","unstructured":"Ludvig DS. The glycemic index physiological mechanisms relating to obesity. diabetes and cardiovascular disease. JAMA 2002; 287 : 2414-3.","journal-title":"JAMA"},{"key":"refR90","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tripleo.2007.06.027","volume":"105","author":"Janket SJ","year":"2008","unstructured":"Janket SJ, Jones JA, Meurman JH, Baird AE, Van Dyke TE. Oral Infection. hyperglycemia and endothelial dysfunction. Oral Sur Oral Med Oral Pathol Oral Radiol Endocrinol 2008; 105 : 173-9.","journal-title":"Oral Sur Oral Med Oral Pathol Oral Radiol Endocrinol"},{"key":"refR91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1876524600902010053","volume":"2","author":"Nakao C","year":"2009","unstructured":"Nakao C, Angel M, Di Mateo S, Komesu MC. Effects of topical tetracycline in wound healing on experimental diabetes in rats. Open Diabetes J 2009; 2 : 53-9.","journal-title":"Open Diabetes J"},{"key":"refR92","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1902\/jop.2007.070140","volume":"78","author":"Mustapha IZ","year":"2007","unstructured":"Mustapha IZ, Debrey S, Oladubu M, Ugarte R. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: a systematic review and meta-analysis. J Periodontol 2007; 78 : 2289-02.","journal-title":"J Periodontol"},{"key":"refR93","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/01.ATV.0000189155.75833.c7","volume":"25","author":"Grundy SM","year":"2005","unstructured":"Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart.Lung and Blood Institute. Atheroscler Thromb Vasc Biol 2005; 25 : 2243-4.","journal-title":"Atheroscler Thromb Vasc Biol"},{"key":"refR94","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1902\/jop.2012.110605","volume":"83","author":"Fukui N","year":"2012","unstructured":"Fukui N, Shimazaki Y, Shinagawa T, Yamashita Y. Periodontal status and metabolic syndrome in middle-aged Japanese. J Periodontol 2012; 83 : 1363-71.","journal-title":"J Periodontol"},{"key":"refR95","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1600-051X.2011.01756.x","volume":"38","author":"Kwon YE","year":"2011","unstructured":"Kwon YE, Ha JE, Paik DI, Jin BH, Bae KH. The relationship between periodontitis and metabolic syndrome among a Korean nationally representative sample of adults. J Clin Periodontol 2011; 38 : 781-6.","journal-title":"J Clin Periodontol"},{"key":"refR96","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1902\/jop.2009.090218","volume":"80","author":"Kushiyama M","year":"2009","unstructured":"Kushiyama M, Shimazaki Y, Yamashita Y. Relationship between metabolic syndrome and periodontal disease in Japanese adults. J Periodontol 2009; 80 : 1610-5.","journal-title":"J Periodontol"},{"key":"refR97","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1210\/jc.2007-2522","volume":"93","author":"D\u2019Aiuto F","year":"2008","unstructured":"D\u2019Aiuto F, Sabbah W, Netuveli G . Association of nthe metabolic syndrome with severe periodontitis in a large US population-based survey. J Clin Endocrinol Metab 2008; 93 : 3989-94.","journal-title":"J Clin Endocrinol Metab"},{"key":"refR98","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1111\/j.1467-789X.2010.00808.x","volume":"12","author":"Suvan J","year":"2011","unstructured":"Suvan J, D\u2019Aiuto F, Moles DR, Petrie A, Donos N. Association between overweight\/obesity and periodontitis in adults: a systematic review. Obesity Reviews 2011; 12 : e404-81.","journal-title":"Obesity Reviews"},{"key":"refR99","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1902\/jop.2010.100321","volume":"81","author":"Chaffee BW","year":"2010","unstructured":"Chaffee BW, Weston SJ. Association between chronic periodontal disease and obesity: a systematic review and meta-analysis. J Periodontol 2010; 81 : 1708-24.","journal-title":"J Periodontol"},{"key":"refR100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-051X.2011.01824.x","volume":"39","author":"Gorman A","year":"2012","unstructured":"Gorman A, Kaye EK, Apovian C, Fung TT, Nunn M, Garcia RI. Overweight and obesity predict time to periodontal periodontal disease progression in men. J Clin Periodontol 2012; 39 : 107-4.","journal-title":"J Clin Periodontol"},{"key":"refR101","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jdiacomp.2004.10.001","volume":"19","author":"Hirsh IB","year":"2005","unstructured":"Hirsh IB, Brownlee M. Should minimum blood glucose variability become the gold standard of glycemic control?. J Diabetes Complicat 2005; 19 : 178-81.","journal-title":"J Diabetes Complicat"},{"key":"refR102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-011-2342-y","volume":"55","author":"Preshaw PM","year":"2012","unstructured":"Preshaw PM, Alba AL, Herrera D. Periodontisis and diabetes: a two-way relationship. Diabetologia 2012; 55 : 21-31.","journal-title":"Diabetologia"},{"key":"refR103","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/01.CIR.0000034509.14906.AE","volume":"106","author":"Esposito K","year":"2002","unstructured":"Esposito K, Nappo F, Marfella R. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106 : 2067-72.","journal-title":"Circulation"},{"key":"refR104","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/187153006778250037","volume":"6","author":"Rahman ZA","year":"2006","unstructured":"Rahman ZA, Soory M. Antioxidant effects of glutathione and IGF in a hyperglycaemic cell culture model of fibroblasts: some actions of advanced glycaemic end products (AGE) and nicotine. Endocr Metab Immune Disord Drug Targets 2006; 6 : 279-86.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"refR105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/187221412799015281","volume":"6","author":"Tilakaratne A","year":"2012","unstructured":"Tilakaratne A, Soory M. Osteoblastic responses to LPS. glucose oxidized LDL and minocycline: therapeutic targets for periodontal and cardiometabolic diseases. Recent Pat Endocr Metab Immune Drug Discov 2012; 6 : 73-84.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"refR106","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1902\/annals.1998.3.1.51","volume":"3","author":"Grossi SG","year":"1998","unstructured":"Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way relationship. Ann Periodontol 1998; 3 : 51-61.","journal-title":"Ann Periodontol"},{"key":"refR107","doi-asserted-by":"crossref","unstructured":"Soory M, El-Shinnawi U, Veas F, Eds. In: Acute phase proteins as early non-specific biomarkers of human and veterinary diseases.Chapter 3: Diagnostic value of acute phase proteins in periodotal.psychosomatic and cardiometabolic diseases response to treatment. In Tech. 2011; pp. 43-68.","DOI":"10.5772\/18048"},{"key":"refR108","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.phrs.2011.06.024","volume":"64","author":"Engebretson SP","year":"2011","unstructured":"Engebretson SP, Hey-Hadavi J. Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study. Pharmacol Res 2011; 64 : 624-9.","journal-title":"Pharmacol Res"},{"key":"refR109","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1902\/jop.2010.100036","volume":"82","author":"Emingil G","year":"2011","unstructured":"Emingil G, Gurkan A, Atilla G, Kantarci A. Sub-antimicrobialdose doxycycline and cytokine-chemokine levels in gingival crevicular fluid. J Periodontol 2011; 82 : 452-61.","journal-title":"J Periodontol"},{"key":"refR110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1902\/jop.2011.110207","volume":"83","author":"Javed F","year":"2012","unstructured":"Javed F, Al-Askar M, Al-Hezaimi K. Cytokine profile in the gingival crevicular fluid of periodontitis patients with and without type 2 diabetes: a literature review. J Periodontol 2012; 83 : 156-61.","journal-title":"J Periodontol"},{"key":"refR111","first-page":"20","volume":"15","author":"Fell RA","year":"2013","unstructured":"Fell RA, Zeek Y, Arora M. The correlation of serum and gingival crevicular fluid cytokines in obese subjects. J Int Acad Periodontol 2013; 15 : 20-8.","journal-title":"J Int Acad Periodontol"},{"key":"refR112","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.phrs.2011.06.013","volume":"64","author":"Federici TJ","year":"2011","unstructured":"Federici TJ. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease. Pharmacol Res 2011; 64 : 614-23.","journal-title":"Pharmacol Res"},{"key":"refR113","first-page":"2","volume":"7","author":"Ogrendik M","year":"2005","unstructured":"Ogrendik M, Kokino S, Ozdemir F, Bird PS, Hamlet S. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. Med Gen Med 2005; 7 : 2-10.","journal-title":"Med Gen Med"},{"key":"refR114","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1002\/art.23936","volume":"58","author":"Lundberg K","year":"2008","unstructured":"Lundberg K, Kinloch A, Fisher BA. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008; 58 : 3009-19.","journal-title":"Arthritis Rheum"},{"key":"refR115","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1002\/art.27552","volume":"62","author":"Wegner N","year":"2010","unstructured":"Wegner N, Wait R, Sroka A. Peptidylarginine deiminase from porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010; 62 : 2662-72.","journal-title":"Arthritis Rheum"},{"key":"refR116","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1902\/jop.2009.080447","volume":"80","author":"Ortiz P","year":"2009","unstructured":"Ortiz P, Bissada NF, Palomo L. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumour necrosis factor inhibitors. J Periodontol 2009; 80 : 535-40.","journal-title":"J Periodontol"},{"key":"refR117","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1902\/jop.2005.76.12.2276","volume":"76","author":"Havemose-Poulsen A","year":"2005","unstructured":"Havemose-Poulsen A, Serensen LK, Stoltze K, Bendtzen K, Holmstrup P. Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis. juvenile idiopathic arthritis and rheumatoid arthritis. J Periodontol 2005; 76 : 2276-85.","journal-title":"J Periodontol"},{"key":"refR118","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2005.036913","volume":"65","author":"Marrotte H","year":"2006","unstructured":"Marrotte H, Farge P, Gaudin P, Alexandre C, Mougin B, Moussec P. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitopes. Ann Rheum Dis 2006; 65 : 905-.","journal-title":"Ann Rheum Dis"},{"key":"refR119","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1600-051X.2010.01552.x","volume":"37","author":"Bartold PM","year":"2010","unstructured":"Bartold PM, Marino V, Cantley M, Haynes DR. Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis. J Clin Periodontol 2010; 37 : 405-11.","journal-title":"J Clin Periodontol"},{"key":"refR120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.autrev.2011.04.001","volume":"10","author":"Ospelt C","year":"2011","unstructured":"Ospelt C, Reedquist KA, Gay S, Tak PP. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis?. Autoimmun Rev 2011; 10 : 519-24.","journal-title":"Autoimmun Rev"},{"key":"refR121","doi-asserted-by":"crossref","first-page":"11829","DOI":"10.3402\/jom.v4i0.11829","volume":"4","author":"Persson GR","year":"2012","unstructured":"Persson GR. Rheumatoid arthritis and periodontitis - inflammatory and infectious connections: review of the literature. J Oral Microbiol 2012; 4 : 11829.","journal-title":"J Oral Microbiol"},{"key":"refR122","first-page":"2112","volume":"30","author":"Stone M","year":"2003","unstructured":"Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis?.Meta-analysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol 2003; 30 : 2112-2.","journal-title":"J Rheumatol"},{"key":"refR123","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.phrs.2011.06.010","volume":"64","author":"Greenwald RA","year":"2011","unstructured":"Greenwald RA. The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacol Res 2011; 64 : 610-3.","journal-title":"Pharmacol Res"},{"key":"refR124","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0765.2005.00843.x","volume":"41","author":"Suzuki A","year":"2006","unstructured":"Suzuki A, Yagisawa J, Kumakura S, Tsutsui T. Effects of minocycline and doxycycline on cell survival and gene expression in human gingival and periodontal ligament cells. J Periodont Res 2006; 41 : 124-31.","journal-title":"J Periodont Res"},{"key":"refR125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2004.02.028","volume":"35","author":"Holmes SG","year":"2004","unstructured":"Holmes SG, Still K, Buttle DJ, Bishop NJ, Grabowski PS. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors. Bone 2004; 35 : 471-8.","journal-title":"Bone"},{"key":"refR126","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S1567-5769(01)00100-X","volume":"1","author":"D\u2019Agostino P","year":"2001","unstructured":"D\u2019Agostino P, Ferlazzo V, Milano S. Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interleukin-12 synthesis in J774 cell line. Int Immunopharmacol 2001; 1 : 1765-76.","journal-title":"Int Immunopharmacol"},{"key":"refR127","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00002018-200022050-00007","volume":"22","author":"Langevitz P","year":"2000","unstructured":"Langevitz P, Livneh A, Bank I, Pras M. Benefits and risks of minocycline in rheumatoid arthritis. Drug Saf 2000; 22 : 405-14.","journal-title":"Drug Saf"},{"key":"refR128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jmb.2010.02.049","volume":"398","author":"Dalm D","year":"2010","unstructured":"Dalm D, Palm GJ, Aleksandrov A, Simonson T, Hinrichs W. Non-antibiotic properties of tetracyclines: struc-tural basis for inhibition of secretory phospholipase A2. J Mol Biol 2010; 398 : 83-96.","journal-title":"J Mol Biol"},{"key":"refR129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/pmic.201000273","volume":"11","author":"Dunston CR","year":"2011","unstructured":"Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB. Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics 2011; 11 : 42-51.","journal-title":"Proteomics"},{"key":"refR130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","volume":"278","author":"Gialeli C","year":"2011","unstructured":"Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278 : 16-27.","journal-title":"FEBS J"},{"key":"refR131","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.4049\/jimmunol.1101174","volume":"188","author":"Kinugawa S","year":"2012","unstructured":"Kinugawa S, Koide M, Kobayashi Y. Tetracyclines convert the osteoclastic-differentiation pathway of progenitor cells to produce dendritic cell-like cells. J Immunol 2012; 188 : 1772-81.","journal-title":"J Immunol"},{"key":"refR132","first-page":"CD007323","author":"da Costa BR","year":"2012","unstructured":"da Costa BR, N\u00fcesch E, Reichenbach S, J\u00fcni P, Rutjes AW. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst Rev Nov1 2012; (11): CD007323.","journal-title":"Cochrane Database Syst Rev Nov1"},{"key":"refR133","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0970-9290.49070","volume":"20","author":"Modi DK","year":"2009","unstructured":"Modi DK, Chopra VS, Bhau U. Rheumatoid arthritis and periodontitis: Biological links and the emergence of dual purpose therapies. Indian J Dent Res 2009; 20 : 86-90.","journal-title":"Indian J Dent Res"},{"key":"refR134","first-page":"199","volume":"6","author":"Gunella G","year":"2006","unstructured":"Gunella G, Bardelli C, Spina S, Fresu LG, Viano I, Brunelleschi S. Anti-inflammatory drugs and tumour necrosis factor alpha production from monocytes: role of transcription factor NF- Kappa B and implications for rheumatoid arthritis therapy. Eur J Pharmacol 2006; 6 : 199-208.","journal-title":"Eur J Pharmacol"},{"key":"refR135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1902\/jop.2004.75.3.453","volume":"75","author":"Lee HM","year":"2004","unstructured":"Lee HM, Ciancio SG, T\u00fcter G, Ryan ME, Komaroff E, Golub LM. Sub-antimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004; 75 : 453-63.","journal-title":"J Periodontol"},{"key":"refR136","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-0757.2006.00170.x","volume":"43","author":"Noguchi K","year":"2007","unstructured":"Noguchi K, Ishikawa I. The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease. Periodontol 2000 2007; 43 : 85-101.","journal-title":"Periodontol 2000"},{"key":"refR137","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1096\/fj.12-214445","volume":"27","author":"Kats A","year":"2013","unstructured":"Kats A, B\u00e5ge T, Georgsson P. Inhibition of microsomal prostaglandin E synthase-1 by aminothiazoles decreases prostaglandin E2 synthesis in vitro and ameliorates experi-mental periodontitis in vivo. FASEB J 2013; 27 : 2328-41.","journal-title":"FASEB J"},{"key":"refR138","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1902\/jop.2002.73.6.585","volume":"73","author":"Tilakaratne A","year":"2002","unstructured":"Tilakaratne A, Soory M. The modulation of androgen metabolism by oestradiol. minocycline and indomethacin in a cell culture model. J Periodontol 2002; 73 : 585-90.","journal-title":"J Periodontol"},{"key":"refR139","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1046\/j.0303-6979.2003.00428.x","volume":"30","author":"Soory M","year":"2003","unstructured":"Soory M, Tilakaratne A. Androgen metabolic response to indomethacin and the alkaline phosphatase inhibitor levamisole in fibroblasts. J Clin Periodontol 2003; 30 : 1069-74.","journal-title":"J Clin Periodontol"},{"key":"refR140","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/BF02978839","volume":"30","author":"Yang JH","year":"2007","unstructured":"Yang JH, Yun MY, Kim DK. Preparation and evaluation of ketorolac tromethamine gel containing genipin for periodontal diseases. Arch Pharm Res 2007; 30 : 871-5.","journal-title":"Arch Pharm Res"},{"key":"refR141","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1194\/jlr.M600151-JLR200","volume":"47","author":"Rahman MM","year":"2006","unstructured":"Rahman MM, Bhattacharya A, Fernandes G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264. cells by modulating RANKL signalling. J Lipid Res 2006; 47 : 1739-48.","journal-title":"J Lipid Res"},{"key":"refR142","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jbspin.2005.10.019","volume":"73","author":"Breuil V","year":"2006","unstructured":"Breuil V, Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006; 73 : 349-54.","journal-title":"Joint Bone Spine"},{"key":"refR143","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/art.21824","volume":"54","author":"Jarrett SJ","year":"2006","unstructured":"Jarrett SJ, Conaghan PG, Sloan VS. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006; 54 : 1410-4.","journal-title":"Arthritis Rheum"},{"key":"refR144","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/ar3376","volume":"13","author":"Calmon-Hamaty F","year":"2011","unstructured":"Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin a revisited: general features and implications in rheumatoid arthritis. Arthritis Res Ther 2011; 13 : 232.","journal-title":"Arthritis Res Ther"},{"key":"refR145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1902\/jop.2005.76.7.1113","volume":"76","author":"Lane N","year":"2005","unstructured":"Lane N, Armitage GC, Loomer P. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month randomized placebo controlled study. J Periodontol 2005; 76 : 1113-22.","journal-title":"J Periodontol"},{"key":"refR146","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1902\/jop.2000.71.12.1862","volume":"71","author":"Kamma JJ","year":"2000","unstructured":"Kamma JJ, Nakou M, Mitsis FJ. The clinical and microbiological effects of systemic ornidazole in sites with and without subgingival debridement in early-onset periodontitis patients. J Periodontol 2000; 71 : 1862-73.","journal-title":"J Periodontol"},{"key":"refR147","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/kel020","volume":"45","author":"Ogrendik M","year":"2006","unstructured":"Ogrendik M, Hakguder A, Keser N. Treatment of rheumatoid arthritis with ornidazole: a randomized double-blind placebo-controlled study. Rheumatology (Oxford) 2006; 45 : 636-7.","journal-title":"Rheumatology (Oxford)"}],"container-title":["The Open Dentistry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/opendentistryjournal.com\/contents\/volumes\/V8\/TODENTJ-8-109\/TODENTJ-8-109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opendentistryjournal.com\/contents\/volumes\/V8\/TODENTJ-8-109\/TODENTJ-8-109.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opendentistryjournal.com\/contents\/volumes\/V8\/TODENTJ-8-109\/TODENTJ-8-109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T11:10:53Z","timestamp":1565521853000},"score":1,"resource":{"primary":{"URL":"https:\/\/opendentistryjournal.com\/VOLUME\/8\/PAGE\/109\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,30]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,5,30]]}},"alternative-id":["TODENTJ-8-109"],"URL":"https:\/\/doi.org\/10.2174\/1874210601408010109","relation":{},"ISSN":["1874-2106"],"issn-type":[{"value":"1874-2106","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2014-2-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-4-8","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-5-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-5-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}